The Market Provides Too Little of the Best Things: The Economics of Positive Externalities

When you get a flu shot, you are buying yourself protection — fewer sick days, a lower chance of a miserable week in bed. That private benefit is what you weigh against the cost of the copay and the trip to the pharmacy. But your shot does something you will never see on a receipt: it makes you a dead end for the virus. Every person you would have infected, and every person they would have infected, is quietly spared. You have delivered a benefit to strangers who did not pay you a cent and whom you will never meet.

That is a positive externality, and it produces a problem that is the exact mirror of pollution. Where a negative externality leads markets to make too much of something harmful, a positive externality leads them to make too little of something beneficial. The market, left alone, systematically under-supplies some of the most valuable things a society can have.

Private benefit, social benefit, and the gap between them

The mechanics rhyme with the negative case but run in reverse. When you decide whether to get vaccinated, you weigh your private benefit — your own reduced risk — against your cost. You do not weigh the social benefit, the much larger total that includes everyone you protect by not spreading the disease. As the Concise Encyclopedia of Economics frames it, an externality is a benefit (or cost) conferred on third parties and not reflected in the price; here the price you face reflects only the slice of value that lands on you.

Because people make decisions on private benefit, and private benefit is smaller than social benefit, fewer people choose the activity than would be ideal. Some who would vaccinate if they were paid for the protection they give others decline, because no one pays them. The result: vaccination rates settle below the level that would be best for the community. The gap between private benefit and social benefit is the engine of the underproduction, just as the gap between private cost and social cost drove the overproduction of pollution.

Why this is the harder failure to feel

Negative externalities announce themselves — you can smell the smoke and see the dead fish. Positive externalities are invisible by construction: the benefit you fail to produce is, by definition, something that never happened. The infections your unbought vaccine would have prevented don't show up anywhere; they are a counterfactual. That invisibility is exactly why markets and individuals chronically undervalue these goods. No one organizes around a harm they never experienced because someone else made a good decision.

This is also why the free market's instinct — leave it to private choice — goes wrong here. Private choice is precisely the mechanism that ignores the spillover. The more diffuse and far-reaching the benefit, the worse the underproduction.

Three goods the market shortchanges

Vaccination is the sharpest case because the externality is large and well-documented. The protection an immunized person gives others is the foundation of herd immunity — once enough of a population is immune, a pathogen can no longer find chains of susceptible hosts and outbreaks fizzle even among the unvaccinated. That community-wide shield is pure positive externality: nobody can be billed for it, so a purely private market for vaccines would buy too few of them. This is why governments subsidize immunization, mandate it for school entry, and often provide it free — the CDC's Vaccines for Children program supplies vaccines at no cost to eligible children precisely to push uptake toward the socially optimal level that private purchasing would miss.

Education spills over for decades. An educated worker earns more — that is the private benefit that motivates the student. But the social benefit is wider: more productive coworkers, higher civic participation, lower crime, innovations that ripple through an economy. The individual deciding whether to finish a degree weighs their own future salary, not the productivity boost their colleagues will get from working alongside them or the inventions their training might eventually seed. Because the private payoff understates the social payoff, a fully private education market would produce less schooling than is socially ideal — a central economic rationale for public funding of education from primary school through research universities.

Basic research may be the most extreme example. When a lab discovers a fundamental principle — the structure of DNA, the math behind public-key encryption — it creates knowledge that countless others build on without paying the original discoverer. The private firm funding the research captures only the sliver it can patent or commercialize; the vast remainder becomes a free input for the entire economy. Because firms can capture so little of the total value they create, private markets badly underinvest in fundamental science. This is the standard justification for government research funding through agencies like the National Science Foundation, whose entire mission rests on the premise that basic research generates social returns far exceeding what any private actor would pay to produce.

A quick worked version

Keep the vaccine example and attach rough numbers. Suppose a flu shot delivers $50 of value to the person who gets it and, on average, prevents enough downstream illness to deliver another $70 of value to others — coworkers not infected, elderly relatives spared, productivity not lost. The social benefit of the shot is $120, but the individual only experiences $50 of it.

Now let the shot cost $60. From a social standpoint, this is a slam-dunk: $120 of benefit for $60 of cost. But the individual sees only $50 of benefit against a $60 cost and rationally declines. A genuinely valuable transaction — $60 in, $120 out — does not happen, because $70 of the payoff goes to people who can't compensate the buyer. Multiply that across millions of marginal decisions and you get a community immunized well below the efficient level.

The fix follows directly: subsidize the shot by, say, $70 — the size of the external benefit — and the individual now faces a net cost that makes vaccinating the obvious choice. The subsidy doesn't bribe people to act against their interest; it simply pays them for the value they create for everyone else, closing the gap between what they capture and what they produce.

Closing the gap

The remedies for positive externalities all do the same job from the opposite direction as a pollution tax: instead of adding the missing cost, they add the missing benefit. A subsidy lowers the price the decision-maker faces by the amount of the spillover, nudging output up to where social benefit equals social cost. A mandate — childhood vaccination requirements, compulsory schooling — forces the efficient quantity directly. Public provision — government-funded research, public universities, free immunization clinics — supplies the good when no private price could ever capture its full value.

The through-line connecting all of this is worth holding onto. Markets are brilliant at producing things whose full value lands on the buyer. They falter precisely when the value leaks outward to people who can't be charged — and the more it leaks, the more the market under-delivers. That is why the goods societies most often choose to subsidize, mandate, or provide directly — vaccines, schools, basic science — are not random. They are the goods whose benefits are too generous, too widely shared, to survive a purely private market intact.